amgen_hq

Amgen slashes price of cholesterol drug Repatha by 60%

pharmafile | October 25, 2018 | News story | Sales and Marketing Repatha, cholestrol, drug, medicine, pricing 

American multinational Amgen has slashed the price of cholesterol drug Repatha, reducing the medication’s US list price by 60%.

The move, which is intended to boost sales, has seen Repatha’s list price drop from $14,000 to $5,850.

Murdo Gordon EVP Global Commercial Operations at Amgen suggested that the price cut, “is clearly focused on helping patients afford the medicine at the pharmacy counter.”

Advertisement

He added that the drug needed to be affordable for those on Medicare, the US government’s health plan for seniors.

Amgen estimated that three quarters of Repatha prescriptions for Medicare patients are not filled due to high out of pocket costs.

“In the long term it is our hope that we can address more patient needs, leading ultimately to higher revenue,” Gordon said.

The new list price is set to come into effect immediately while the old list price will be phased out by the end of 2020.

Pharmacy benefit manager Express Scripts’ Chief Medical Officer Steve Miller commented: “Amgen is taking an important step forward to help payers be better positioned to provide breakthrough medicines and help people achieve better outcomes.”

Louis Goss

Related Content

NICE recommendation for KORSERDU®▼ (elacestrant) marks ‘step-change’ in the treatment of ESR1-mutated metastatic breast cancer

Elacestrant is the first tailored treatment for certain people with oestrogen receptor (ER)-positive HER2-negative locally …

8266471202_63a8f743a9_b_0

Merck, Novartis and Allergan to raise US drug prices, following most of drug industry

Following most of the large pharmaceutical companies, Merck, Novartis and Allergan have chosen to raise …

Senate puts forward bipartisan bill to lower price of drugs

The Senate Finance Committee has introduced a bipartisan bill that aimed at lowering the prices …

The Gateway to Local Adoption Series

Latest content